MEDI 4166

Drug Profile

MEDI 4166

Alternative Names: MEDI4166

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator MedImmune
  • Class Antihyperglycaemics; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action Glucagon like peptide 1 receptor agonists; PCSK9 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cardiovascular disorders; Type 2 diabetes mellitus

Most Recent Events

  • 01 Jan 2016 Phase-II clinical trials in Cardiovascular disorders in USA (unspecified route) (AstraZeneca pipeline, May 2016)
  • 01 Jan 2016 Phase-II clinical trials in Type-2 diabetes mellitus in USA (SC) (AstraZeneca pipeline, May 2016)
  • 01 Oct 2015 Phase-I clinical trials in Type-2 diabetes mellitus in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top